"Breakthrough" drugs and growth in expenditure on prescription drugs in Canada.
نویسندگان
چکیده
Driven by increased use of prescription drugs and by shifts from old to new products, spending on drugs in Canada doubled between 1996 and 2003. Which drugs drove this expenditure growth? The Canadian Patented Medicine Prices Review Board appraises the therapeutic novelty of every patented medicine in Canada to distinguish “breakthrough” drugs from other medicines. Since 1990, the board has published these appraisals in annual reports. We applied the board’s classifications for breakthrough drugs to total expenditures on and use of prescription drugs in the province of British Columbia (population 4.2 million).
منابع مشابه
Universal Pharmacare in Canada: A Prescription for Equity in Healthcare
Despite progressive universal drug coverage and pharmaceutical policies found in other countries, Canada remains the only developed nation with a publicly funded healthcare system that does not include universal coverage for prescription drugs. In the absence of a national pharmacare plan, a province may choose to cover a specific sub-population for certain drugs. Altho...
متن کاملThe Misguided War Against Medicines 2008
Executive summary / 1 Introduction / 7 The particular impact of new or " patented " drugs on government health care costs / 8 The impact of all types of drugs on government health care costs / 18 The real cause of unsustainable growth in government health spending / 25 Research suggests that government health spending in Canada is growing at an unsus-tainable pace [Skinner and Rovere, 2006; 200...
متن کاملPharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007–13) and prospective (2014–18) MIDAS sales data analysis
BACKGROUND Health Canada has defined rare diseases as life-threatening, seriously debilitating, or serious chronic conditions affecting a very small number of patients (~1 in 2,000 persons). An estimated 9 % of Canadians suffer from a rare disease. Drugs treating rare diseases (DRDs) are also known as orphan drugs. While Canada is currently developing an orphan drug framework, in the United Sta...
متن کاملNational Pharmacare in Canada: Equality or Equity, Accessibility or Affordability; Comment on “Universal Pharmacare in Canada: A Prescription for Equity in Healthcare”
Canada’s federal government intends to take steps to implement national pharmacare so that all Canadians have prescription drug coverage they need at an affordable price. Relatively limited funds have so far been pledged to support national pharmacare, which raises the question: what kind of program is envisioned? Since the government has already introduced regulations intended to reduce new dr...
متن کاملCost-Sharing Rates Increase During Deep Recession: Preliminary Data From Greece
Background Measures taken over the past four years in Greece to reduce pharmaceutical expenditure have led to significant price reductions for medicines, but have also changed patient cost-sharing rates for prescription drugs. This study attempts to capture the resulting increase in patients’ out-of-pocket (OOP) expenses for prescription drugs during the 2011-2014 period. Methods The authors ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- BMJ
دوره 331 7520 شماره
صفحات -
تاریخ انتشار 2005